|
PXL/HO/Cir-023/2025-26 Date: 28.05.2025
Hyderabad
Subject: Report on Pharmaceutical & Vaccine Procurement Processes in Norway – Study Commissioned by the Indian Embassy, Oslo
Dear Members,
We are pleased to inform you that the Indian Embassy in Oslo, Norway, with support from the Ministry of Commerce under the Market Expansion Activity (MEA), commissioned a study on the procurement processes for pharmaceuticals and vaccines in Norway. This report provides valuable insights into the Norwegian pharmaceutical landscape, emphasizing the importance of early regulatory engagement, local partnerships, and price-sensitive strategies in alignment with Norway’s healthcare priorities.
Key Highlights of the Report:
-
Market Overview:Analysis of the structure and dynamics of Norway’s pharmaceutical sector.
-
Regulatory Framework:Detailed guidance on compliance with EMA and the Norwegian Medical Products Agency (NoMA).
-
Procurement Channels: Insights into the procurement of in-patient, out-patient pharmaceuticals, and vaccines.
-
Stakeholders & Distribution:Identification of key entities including NoMA, Ministry of Health, Sykehusinnkjøp HF, wholesalers, hospital pharmacies, and distributors.
-
Support Mechanisms:Overview of schemes like Innovation Norway and SkatteFUNN supporting market entry and expansion.
-
Practical Guidance: Step-by-step recommendations for Indian companies navigating Norway’s regulatory and operational environment.
-
FAQs: Answers to frequently asked questions by Indian exporters regarding the Norwegian market.
-
This study is particularly relevant in the context of the Trade and Economic Partnership Agreement (TEPA) and serves as a useful reference for Indian pharmaceutical companies exploring opportunities in Norway and the broader Nordic region.
We encourage member companies interested in the Norwegian market to make full use of this report. For further queries, please write to us at dgdesk@pharmexcil.com
Warm regards,
Raja Bhanu
Director General
Encl: Report
|
